Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine

Malaria Journal

Case Report

Chanthap Lon¹  Soklyda Chann¹  Mali Ittiverakul²  Charlotte A Lanteri²  Nillawan Buathong²  David L Saunders²  Worachet Kuntawunginn²  Michele Spring²  Somethy Sok³  Rathvichet Bun⁴  Nareth Kong⁴  Yom You⁴  Khengheng Thay⁴ 

[1] Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), Phnom Penh, Cambodia;Department of Immunology and Medicine, US Army Medical Corps, Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), Bangkok, Thailand;Royal Cambodian Armed Forces, Phnom Penh, Cambodia;The National Center for Parasitology, Entomology and Malaria Control (CNM), Ministry of Health, Phnom Penh, Cambodia;

关键词: Malaria;    Plasmodium falciparum;    Cambodia;    Blackwater fever;    Dihydroartemisinin-piperaquine;   

DOI  :  10.1186/1475-2875-13-96

 received in 2014-02-19, accepted in 2014-03-06,  发布年份 2014

来源: Springer

【 摘 要 】

The mechanism of massive intravascular haemolysis occurring during the treatment of malaria infection resulting in haemoglobinuria, commonly known as blackwater fever (BWF), remains unknown. BWF is most often seen in those with severe malaria treated with amino-alcohol drugs, including quinine, mefloquine and halofantrine. The potential for drugs containing artemisinins, chloroquine or piperaquine to cause oxidant haemolysis is believed to be much lower, particularly during treatment of uncomplicated malaria. Here is an unusual case of BWF, which developed on day 2 of treatment for uncomplicated Plasmodium falciparum infection with dihydroartemisinin-piperaquine (DHA-PIP) with documented evidence of concomitant seropositivity for Chikungunya infection.

【 授权许可】

CC BY   
© Lon et al.; licensee BioMed Central Ltd. 2014